First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.
2018
2505Background: A phase I study was done to establish the safety, MTD and anti-tumour efficacy of the novel PARP 1/2 and Tankyrase 1/2 inhibitor, 2X-121 (E7449). A novel tumor agnostic molecular bi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI